Over-suppression of bone turnover: Does it exist?
- Juliet Compston
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Bone-turnover suppression is central to the therapeutic benefit of many interventions used to prevent osteoporotic fractures. There are theoretical concerns that long-term suppression may have adverse effects on bone strength, although at present no direct evidence exists that this happens. Nevertheless, further research is required to establish the optimal duration of treatment with antiresorptive agents.
- Frost HM: Dynamics of bone remodeling. In Bone Biodynamics. Edited by Frost HM. Boston: Little, Brown and Co.; 1964:315–333.
- Parfitt AM: The cellular basis of bone remodeling. The quantum concept re-examined in light of recent advances in cell biology. Calcif Tiss Int 1984, 36:S37–S45. CrossRef
- Eriksen EF: Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986, 7:378–408. CrossRef
- Frost HM: Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 1969, 3:211–237. CrossRef
- Compston JE, Croucher PI: Histomorphometric assessment of trabecular bone remodeling in osteoporosis. Bone Miner 1991, 14:91–102. CrossRef
- Parfitt AM, Drezner MK, Glorieux FH, et al.: Bone histomorphometry: standardisation of nomenclature, symbols and units. J Bone Miner Res 1987, 2:595–610.
- Compston JE, Vedi S, Kaptoge S, Seeman E: Bone remodeling rate and remodeling balance are not co-regulated in adulthood: implications for the use of activation frequency as an index of remodeling rate. J Bone Miner Res 2007, 22:1031–1036. CrossRef
- Seibel MJ: Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000, 6:S18–S29. CrossRef
- Eventov I, Frisch B, Cohen Z, Hammel I: Osteopenia, hematopoiesis, and bone remodeling in iliac crest and femoral biopsies: a prospective study of 102 cases of femoral neck fractures. Bone 1991, 12:1–6. CrossRef
- Abildgaard N, Glerup H, Rungby J, et al.: Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Europ J Haematol 2000, 64:121–129. CrossRef
- Delmas PD, Seeman E: Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 2004, 34:599–604. CrossRef
- Riggs BL, Melton LJ III: Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002, 17:11–14. CrossRef
- Eriksen EF, Hodgson SF, Eastell R, et al.: Cancellous bone remodeling in type I [postmenopausal] osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res 1990, 5:311–319.
- Wright CDP, Vedi S, Garrahan NJ, et al.: Combined inter-observer and inter-method variation in bone histomorphometry. Bone 1992, 13:205–208. CrossRef
- Adachi JD, Cranny A, Goldsmith CH, et al.: Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss. J Rheumatol 1994, 21:1922–1926.
- Saag KG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292–299. CrossRef
- Reid DM, Hughes RA, Laan RF, et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trial. J Bone Miner Res 2000, 15:1006–1013. CrossRef
- Chavassieux PM, Arlot ME, Roux JP, et al.: Effect of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000, 15:754–762. CrossRef
- Black DM, Delmas PD, Eastell R, et al.: Once-yearly zole-dronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809–1822. CrossRef
- Recker RR, Weinstein RS, Chesnut CH, et al.: Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004, 15:231–237. CrossRef
- Eriksen EF, Melsen F, Sod E, et al.: Effects of risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002, 31:620–625. CrossRef
- Storm T, Steiniche T, Thamsborg G, Melsen F: Changes in bone histomorphometry after long-term treatment with intermittent cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 1993, 8:199–208. CrossRef
- Prestwood KM, Gunness M, Muchmore DB, et al.: A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000, 85:2197–2202. CrossRef
- McClung MR, Lewiecki EM, Cohen SB, et al.: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821–831. CrossRef
- Eastell R, Barton I, Hannon RA, et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051–1056. CrossRef
- Vedi S, Croucher PI, Garrahan NJ, Compston JE: Effects of hormone replacement therapy on cancellous bone microstructure in postmenopausal women. Bone 1996, 19:69–72. CrossRef
- Borah B, Dufresne TE, Chmielewski PA, et al.: Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004, 34:736–746. CrossRef
- Dufresne TE, Chmielewski PA, Manhart MD, et al.: Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003, 73:423–432. CrossRef
- Roschger P, Rinnerthaler S, Yates J, et al.: Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185–191. CrossRef
- Boivin G, Chavassieux PM, Santora AC, et al.: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687–694. CrossRef
- Boivin G, Vedi S, Purdie DW, et al.: Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. Bone 2005, 36:562–567. CrossRef
- Borah B, Ritman EL, Dufresne TE, et al.: The effect of risedronate on bone mineralization as measured by microcomputed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005, 17:1–9. CrossRef
- Paschalis EP, Verdelis K, Doty SB, et al.: Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 2001, 16:1821–1828. CrossRef
- Wang XF, Shen X, Li X, Agrawal CM: Age-related changes in the collagen network and toughness of bone. Bone 2002, 31:1–7. CrossRef
- Vashishth D, Gibson GJ, Khoury JI, et al.: Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001, 28:1–7. CrossRef
- Paschalis EP, Shane E, Lyritis G, et al.: Bone fragility and collagen cross-links. J Bone Miner Res 2004, 19:2000–2004. CrossRef
- Burr DB: Targeted and non-targeted remodeling. Bone 2002, 30:2–4. CrossRef
- Sorensen OH, Crawford GM, Mulder H, et al.: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120–126. CrossRef
- Mellström DD, Sorensen OH, Goemare S, et al.: Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:462–468. CrossRef
- Delmas PD, Ensrud KE, Adachi JD, et al.: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomised clinical trial. J Clin Endocrinol Metab 2002, 87:3609–3617. CrossRef
- Reginster JY, Meunier PJ, Roux C, et al.: Strontium ranelate, an anti-osteoporotic treatment, demonstrated vertebral and nonvertebral anti-fracture efficacy over 5 years in postmenopausal osteoporotic women. Osteoporos Int 2006, 17:S14.
- Bone HG, Hosking D, Devogelaer JP, et al.: Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189–1199. CrossRef
- Black DM, Schwartz AV, Ensrud KE, et al.: Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A randomised trial. JAMA 2006, 296:2927–2938. CrossRef
- Odvina CV, Zerwekh JE, Rao DS, et al.: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294–1301. CrossRef
- Schneider JP: Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006, 61:31–33.
- Recker R, Ensrud K, Diem S, et al.: Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res 2004, 19(Suppl 1):45.
- Over-suppression of bone turnover: Does it exist?
Current Osteoporosis Reports
Volume 5, Issue 4 , pp 179-185
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Juliet Compston (1)
- Author Affiliations
- 1. Department of Medicine, Addenbrooke’s Hospital, Box 157, Cambridge, CB2 2QQ, UK